P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB

• Ida H. Hiemstra,
• Kim Santegoets,
• Maarten Janmaat,
• Wessel Ten Hagen,
• Rosanna Sanchez,
• Lauren Brady,
• Sieto Bosgra,
• Marije Overdijk,
• Jenny Chen,
• Katrine Fladeland Iversen,
• Torben Plesner,
• Esther Breij

Affiliations

Ida H. Hiemstra

1 Genmab BV, Utrecht, The Netherlands

Kim Santegoets

1 Genmab BV, Utrecht, The Netherlands

Maarten Janmaat

1 Genmab BV, Utrecht, The Netherlands

Wessel Ten Hagen

1 Genmab BV, Utrecht, The Netherlands

Rosanna Sanchez

1 Genmab BV, Utrecht, The Netherlands

Lauren Brady

2 Genmab US, Plainsboro, United States

Sieto Bosgra

1 Genmab BV, Utrecht, The Netherlands

Marije Overdijk

1 Genmab BV, Utrecht, The Netherlands

Jenny Chen

2 Genmab US, Plainsboro, United States

Katrine Fladeland Iversen

3 Vejle Hospital, Vejle, Denmark

Torben Plesner

3 Vejle Hospital, Vejle, Denmark

Esther Breij

1 Genmab BV, Utrecht, The Netherlands